Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Non-Current Liabilities: 2014-2024

Historic Other Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2024 value amounting to $10.6 million.

  • Gyre Therapeutics' Other Non-Current Liabilities fell 70.04% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 70.04%. This contributed to the annual value of $10.6 million for FY2024, which is 39.46% down from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Other Non-Current Liabilities is $10.6 million, which was down 39.46% from $17.6 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Other Non-Current Liabilities ranged from a high of $17.6 million in FY2023 and a low of $55,000 during FY2022.
  • Its 3-year average for Other Non-Current Liabilities is $9.4 million, with a median of $10.6 million in 2024.
  • As far as peak fluctuations go, Gyre Therapeutics' Other Non-Current Liabilities spiked by 31,821.82% in 2023, and later crashed by 39.46% in 2024.
  • Yearly analysis of 3 years shows Gyre Therapeutics' Other Non-Current Liabilities stood at $55,000 in 2022, then skyrocketed by 31,821.82% to $17.6 million in 2023, then crashed by 39.46% to $10.6 million in 2024.